Healthcare
Profound Medical Corp.(PROF)
Live Price
Offline$6.63
-0.38% today
1Y Change
+11.65%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $210.00M
- Revenue Growth
- +58.3%
- EPS Growth
- +231.8%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Profound Medical Corp. (PROF) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $6.63 and up 11.6% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +58.3%, EPS growth of +231.8%, a dividend yield of 0.0%. What stands out right now is revenue +58.3%, EPS +231.8%, free cash flow -128.5% with operating margin -239.5% and ROIC -23.8%. Valuation already assumes a fairly strong business story at price/sales 11.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PROF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+58.3% vs +7.6% peer median
Operating Margin
Below sector median
-239.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +58.3% and EPS at +231.8%, with operating margin around -239.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -12.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.2% | -3.2% | -8.0% |
2026 Mar 5, 2026 | +0.0% | -29.1% | -25.9% | -14.2% |
2025 Nov 13, 2025 | +31.6% | +7.9% | -7.5% | +15.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PROF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PROF Max Drawdown
-41.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PROF and SPY.
Company Overview
Profound Medical Corp.
NASDAQ Capital Market
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
- Leadership
- Arun Swarup Menawat
- IPO Date
- Oct 29, 2019
- Employees
- 142
- Street Address
- 2400 Skymark Avenue
- Mailing
- Mississauga, ON, L4W 5K5
- Region
- Mississauga, ON, CA
- Reporting Currency
- USD
- Investor Line
- 16474761350
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 11.4
- Price/Book
- 2.3
Growth
- Revenue
- +58.3%
- EPS
- +231.8%
- Free Cash Flow
- -128.5%
Profitability
- Gross Margin
- 70.2%
- Operating Margin
- -239.5%
- Net Margin
- -248.5%
- ROE
- -85.7%
- ROIC
- -23.8%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 12.52
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.